What does this research mean for the field?

In real-world emergency settings, appropriate administration of prothrombin complex concentrates (PCC) for vitamin K antagonist reversal is achieved in only a minority of patients, with significant delays in treatment delivery and inadequate monitoring. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

March 3, 2026

Emergency reversal of anticoagulation : the real use of prothrombin complex concentrates: a prospective multicenter two year French study from 2006 to 2008

Key Points

An appropriate treatment with PCC was documented in only 26% of patients, highlighting inadequate administration protocols.
The study showed that a PCC dose of 20-30 UI/kg successfully reduced INR to below 1.5 in 65% of cases, suggesting this range is effective.

Structured PICO

Population

Patients receiving prothrombin complex concentrate (PCC) for reversal of vitamin K antagonist (VKA) / oral anticoagulant therapy (OAT) in emergency departments

Intervention

Prothrombin complex concentrate (PCC)

Outcome

Appropriate treatment (defined as PCC recommended, dose >= 20 UI/kg, with vitamin K, and INR assessment after PCC)

Real-world emergency use of PCC for VKA reversal frequently fails to meet appropriate treatment criteria, highlighting a need for improved administration protocols, timeliness, and INR monitoring.

Abstract

Introduction: Prothrombin complex concentrate (PCC) for reversal of vitamin K antagonist (VKA) is the main therapeutic option in cases of life-threatening bleeding. Clinical use of PCC is poorly documented. Methods: We prospectively assessed PCC use in four French emergency departments during a two year period 2006-2008 before publication of French Guidelines. An appropriate treatment was defined when PCC was recommended, with a dose of PCC above or equal to 20 UI/kg, with vitamin K and with an assessment of international normalized ratio (INR) after PCC. Time of diagnosis and PCC administration were collected, as INR values, thromboembolic events within seven days, hospital mortality. Results: 256 patients received PCC for reversal of OAT. PCC was mainly prescribed for major intracerebral (ICH) or gastrointestinal hemorrhage. An appropriate treatment was observed in 26% of patients. Intra-hospital mortality for major bleeding was 33% for ICH and 26% for non-ICH major bleeding. A PCC dose>20 UI/kg was able to reach an INRConclusion: A suitable treatment was administered in 26% of patients. A PCC dose of 20-30 IU/kg seems adequate in most cases to reverse VKA activity, but both higher and lower doses achieve similar effects. Considerable progress is required to improve PCC administration and control of treatment efficacy, and to shorten time to diagnosis.

Mark Helpful

Bookmark

Relay